Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California–San Francisco experience

Lee, Brian; Shinohara, Katsuto; Weinberg, Vivian; Gottschalk, Alexander; Pouliot, Jean; Roach, Mack; Hsu, I-Chow

doi:10.1016/j.ijrobp.2006.10.012

Cited by 122 publications

(58 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Usually, 125 I and 103 Pd are widely used as the radioactive isotopes. Lee et al [23] reported on HDR salvage brachytherapy and pointed out that in some cases, HDR therapy could decrease the incidence of GU toxicity compared to LDR brachytherapy.…”

Section: Discussionmentioning

confidence: 99%

Salvage <sup>125</sup>I Seed Implantation for Prostate Cancer with Postradiation Local Recurrence

Shimbo¹,

Inoue

Koike³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Introduction: Although radiotherapy has been important in the therapy for localized prostate cancer, prostate-specific antigen failure may occur. This study evaluated the effects and side effects of ¹²⁵I low-dose-rate brachytherapy for patients with postradiation local failure. Patients and Methods: 15 patients who received salvage brachytherapy were analyzed. A prescribed dose of 144 Gy was selected. Median follow-up calculated from the date of salvage brachytherapy was 33.0 months (range 6-51). Results: 5 patients (33.3%) developed prostate-specific antigen failure. The biochemical relapse-free survival rate was 100% at 1 year, 91.7% at 2 years, and 60.2% at 3 years. All acute genitourinary and gastrointestinal adverse events were in grade 1-2 according to Common Terminology Criteria for Adverse Events version 3. As for late adverse events, 1 patient (6.7%) developed grade 3 hematuria at 17 months postsalvage. Conclusions: Although careful patient selection is needed, salvage ¹²⁵I prostate brachytherapy appears to provide good prostate cancer control with an acceptable rate of complications for patients with local recurrence of prostate cancer after initial radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Salvage <sup>125</sup>I Seed Implantation for Prostate Cancer with Postradiation Local Recurrence

Shimbo¹,

Inoue

Koike³

et al. 2013

Urol Int

View full text Add to dashboard Cite

show abstract

“…A recent report from the University of California at San Francisco (n 5 21) evaluated high-dose-rate salvage brachytherapy. 46 Estimated biochemical control at 2 years was 89%, with 18 patients reported to have had grade 1 or 2 complications and 3 patients who developed grade 3 genitourinary complications.…”

Section: Salvage Brachytherapymentioning

confidence: 94%

Management of prostate cancer recurrences after radiation therapy‐brachytherapy as a salvage option

Allen

Howard

Jarrard

et al. 2007

Cancer

View full text Add to dashboard Cite

Depending on initial prognostic factors, an estimated 10%-60% of men who undergo definitive radiation therapy for prostate cancer may experience a biochemical recurrence. Even though hormonal therapy is standard for metastatic recurrences, no consensus exists on optimal salvage therapy for those recurrences thought confined to the prostate. Salvage treatment options for these local recurrences have historically been limited to salvage prostatectomy, hormonal therapy, or cryotherapy. Salvage prostate brachytherapy, however, uses a widely available technique and may provide another option for attaining disease control in patients with localized failures, although only about 110 cases have been reported in the literature. In this report, the authors have described their own series of salvage brachytherapy cases as well as presented a review of other such series reported in the literature. In addition, the authors included a comprehensive review of published experiences with surgery and cryotherapy as salvage options. It appears that salvage brachytherapy, when combined with careful patient selection, is at least as effective as other salvage options with comparable or potentially fewer treatment-related side effects.

show abstract

“…The limited data in the literature regarding re-irradiation of such patients focuses on HDR brachytherapy [65][66][67]. Nevertheless, it would seem imperative for patients whose prostates are being re-irradiated to severely limit the urethral dose.…”

Section: Sbrt For Recurrent Diseasementioning

confidence: 99%

Stereotactic body radiotherapy for prostate cancer: ready for prime time?

Katz

2012

J Radiat Oncol

View full text Add to dashboard Cite

Stereotactic body radiotherapy (SBRT) delivers a few high doses of radiation to a target in the body with extreme accuracy and conformality. Prostate cancer's great sensitivity to dose per fraction allows SBRT's hypofractionated delivery the opportunity to increase the biological equivalent dose delivered to the prostate while relatively decreasing the dose to the normal bladder and rectal tissues. In recent years, clinical outcomes supporting the safety and increasingly longer-term efficacy of SBRT have been published. This review examines the basis of hypofractionation, current SBRT delivery mechanisms, and the growing body of clinical outcomes of SBRT for prostate cancer. In addition, given the increased interest in SBRT for prostate cancer, clinical issues in the treatment of prostate cancer with SBRT and a look into the future of SBRT for prostate cancer are examined.

show abstract

Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California–San Francisco experience

Cited by 122 publications

References 33 publications

Salvage <sup>125</sup>I Seed Implantation for Prostate Cancer with Postradiation Local Recurrence

Salvage <sup>125</sup>I Seed Implantation for Prostate Cancer with Postradiation Local Recurrence

Management of prostate cancer recurrences after radiation therapy‐brachytherapy as a salvage option

Stereotactic body radiotherapy for prostate cancer: ready for prime time?

Contact Info

Product

Resources

About